Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: A randomised controlled study

Aging Male

Volumn 14, Issue 1, 2011, Pages 53-58

  Shigehara, Kazuyoshi ^a   Sugimoto, Kazuhiro ^a   Konaka, Hiroyuki ^a   Iijima, Masashi ^a   Fukushima, Masato ^a   Maeda, Yuji ^a   Mizokami, Atsushi ^a   Koh, Eitetsu ^a   Origasa, Hideki ^c   Iwamoto, Teruaki ^b   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Androgen replacement therapy; benign prostate hypertrophy; hypogonadism; lower urinary tract symptoms; post voiding residual volume; uroflowmetry

Indexed keywords

ENARMONE DEPOT; TESTOSTERONE ENANTATE; UNCLASSIFIED DRUG;

AGED; ANDROGEN THERAPY; ARTICLE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HYPOGONADISM; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MUSCLE MASS; OUTCOME ASSESSMENT; POST VOIDING RESIDUAL VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; URINE FLOW RATE; URINE VOLUME; UROFLOWMETRY;

AGE FACTORS; AGED; AGING; ANDROGENS; DISEASE PROGRESSION; HEALTH STATUS INDICATORS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MEN'S HEALTH; PROSTATIC HYPERPLASIA; QUESTIONNAIRES; TESTOSTERONE; URODYNAMICS; UROLOGIC DISEASES;

EID: 79751520081     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.3109/13685538.2010.518178     Document Type: Article

References (30)

1. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, McKinlay JB. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89:5920-5926. (Pubitemid 39628393)
2. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 2009;5:427-448.
3. Comhaire FH. Andropause: hormone replacement therapy in the ageing male. Eur Urol 2000;38:655-662.
4. Morales A, Lunenfeld B. Standards, guidelines and recommendations of the international society for the study of the aging male (ISSAM). Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. Aging Male 2002;5:74-86.
5. Lunenfeld B, Saad F, Hoesl CE. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale. Aging Male 2005;8:59-74. (Pubitemid 40978895)
6. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B,Morley JE, Schulman C,Wang C, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2005;8:56-58. (Pubitemid 40978894)
7. Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009;12:5-12.
8. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT Study. Eur Urol 2010;57:123-131.
9. Homma Y, Kawabe K, Tsukamoto T, Yamaguchi O, Okada K, Aso Y, Watanabe H, Okajima E, Kumazawa J, Yamaguchi T, et al. Estimate criteria for diagnosis and severity in benign prostatic hyperplasia. Int J Urol 1996;3:261-266. (Pubitemid 26264297)
10. Namiki M, Akaza H, Shimazui T, Ito N, Iwamoto T, Baba K, Kumano H, Koh E, Tsujimura A, Matsumiya K, et al. Clinical practice manual for late-onset hypogonadism syndrome. Int J Urol 2008;15:377-388. (Pubitemid 351623887)
11. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479. (Pubitemid 14026148)
12. Huggins C, Stevens RE Jr, Hodges CV. Studies on prostatic cancer. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209-223.
13. Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999;59:4161-4164. (Pubitemid 29418717)
14. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75:1092-1098.
15. Holmäng S, Ma°rin P, Lindstedt G, Hedelin H. Effect of longterm oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate 1993;23:99-106. (Pubitemid 23289891)
16. Franchi F, Luisi M, Kicovic PM. Long term study of testosterone undecanoate in hypogonadal males. Int J Androl 1978;1:270-278. (Pubitemid 9044369)
17. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994;15:212-215. (Pubitemid 24218140)
18. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006;296:2351-2361. (Pubitemid 44749363)
19. Pechersky AV, Mazurov VI, Semiglazov VF, Karpischenko AI, Mikhailichenko VV, Udintsev AV. Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl 2002;25:119-125. (Pubitemid 34298083)
20. Slater S, Oliver RT. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000;17:431-439. (Pubitemid 32102726)
21. Karazindiyano-glu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male 2008;11:146-149.
22. Celayir S. Effects of different sex hormones on male rabbit urodynamics: an experimental study. Horm Res 2003;60:215-220. (Pubitemid 37465082)
23. Madeiro A, Girão M, Sartori M, Acquaroli R, Baracat E, Rodrigues De Lima G. Effects of the association of androgen/ estrogen on the bladder and urethra of castrated rats. Clin Exp Obstet Gynecol 2002;29:117-120. (Pubitemid 34815257)
24. Traish AM, Goldstein I, Kim NN. Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol 2007;52:54-70. (Pubitemid 46803026)
25. Cayan F, Tek M, Balli E, Oztuna S, Karazindiyanoglu S, Cayan S. The effect of testosterone alone and testosterone+ estradiol therapy on bladder functions and smooth muscle/ collagen content in surgically menopause induced rats. Maturitas 2008;60:248-252.
26. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006;97 (Suppl 2):23-28. (Pubitemid 43356992)
27. Mitterberger M, Pallwein L, Gradl J, Frauscher F, Neuwirt H, Leunhartsberger N, Strasser H, Bartsch G, Pinggera GM. Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. BJU Int 2007;99:831-835. (Pubitemid 46439584)
28. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005;47:838-845. (Pubitemid 40745354)
29. Azadzoi KM, Tarcan T, Kozlowski R, Krane RJ, Siroky MB. Overactivity and structural changes in the chronically ischemic bladder. J Urol 1999;162:1768-1778. (Pubitemid 29474727)
30. Okutsu H, Matsumoto S, Hanai T, Noguchi Y, Fujiyasu N, Ohtake A, Suzuki M, Sato S, Sasamata M, Uemura H, et al. Effects of tamsulosin on bladder blood flow and bladder function in rats with bladder outlet obstruction. Urology 2010;75:235-240.